Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Trajan Group HoldingsASX:TRJ -10.34%38 EBITDA Margin % is 3.65% as of Dec. 2025, which is 14% below its 10-year median of 4.22. GuruFocus rates ASX:TRJ with a GF Score™ of 38/100 and a GF Value™ of A$1.11 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 817 Medical Devices & Instruments companies, Trajan Group Holdings ranks worse than 53.98% on this metric.
Trajan Group Holdings (ASX:TRJ) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Trajan Group Holdings EBITDA Margin % Related Terms
Trajan Group Holdings EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Trajan Group Holdings's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:TRJ vs ISRG, BDX, MDLN: EBITDA Margin % Comparison
For the Medical Instruments & Supplies subindustry, Trajan Group Holdings's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Trajan Group Holdings EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Trajan Group Holdings's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Trajan Group Holdings's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Trajan Group Holdings (ASX:TRJ) has a EBITDA Margin % of 3.65% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Trajan Group Holdings and its competitors. This is 14% below median its historical median of 4.22. According to the industry distribution chart, Trajan Group Holdings ranks #441 out of 817 companies in the Medical Devices & Instruments industry, placing it in the top 54%.
Is Trajan Group Holdings' EBITDA Margin % too high?
Trajan Group Holdings' current EBITDA Margin % of 3.65% is 14% below median its 10-year median of 4.22. The Medical Devices & Instruments industry median EBITDA Margin % is 7.44. Trajan Group Holdings' value of 3.65% is 50.9% below this industry median. Based on the distribution chart, Trajan Group Holdings ranks #441 out of 817 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Trajan Group Holdings has a GF Score™ of 38/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Trajan Group Holdings' EBITDA Margin % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Trajan Group Holdings ranks #441 out of 817 companies for EBITDA Margin %. This places Trajan Group Holdings in the lower half of its industry. The industry median EBITDA Margin % is 7.44. Trajan Group Holdings' value of 3.65% is 50.9% below this benchmark. While the company's 10-year median is 4.22 vs. the industry median of 7.44, Trajan Group Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.44, based on 817 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Trajan Group Holdings's current EBITDA Margin % of 3.65% is 50.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Trajan Group Holdings and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Trajan Group Holdings's current EBITDA Margin % is 3.65%, which is 14% below median its own 10-year median of 4.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Trajan Group Holdings stock overvalued right now?
Based on GuruFocus' analysis, Trajan Group Holdings (ASX:TRJ) is currently considered Possible Value Trap. The stock's GF Value™ is A$1.11, compared to a current price of A$0.26 — trading 76.6% below its estimated fair value. The current EBITDA Margin % is 3.65%, which is 14% below median its 10-year median of 4.22 and 50.9% below the Medical Devices & Instruments industry median of 7.44. Trajan Group Holdings' overall GF Score™ is 38/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Trajan Group Holdings (ASX:TRJ), the current EBITDA Margin % is 3.65% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Trajan Group Holdings (ASX:TRJ) Overvalued in 2026?
Based on GuruFocus' analysis, Trajan Group Holdings stock appears to be undervalued.
The current stock price of A$0.26 is trading 76.6% below its estimated GF Value™ of A$1.11.
GuruFocus considers Trajan Group Holdings to be Possible Value Trap.
Key valuation signals for ASX:TRJ:
EBITDA Margin %: 3.65% (14% below median its 10-year median of 4.22)
GF Value™: A$1.11 vs. price of A$0.26 (76.6% below fair value)
Industry Position: 50.9% below the Medical Devices & Instruments median (#441 of 817)
No single metric tells the full story. See the ASX:TRJ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Trajan Group Holdings Ltd is a developer and manufacturer of analytical and life sciences products and devices, seeking to enrich human well-being through scientific measurement. Its current portfolio of products comprises products, devices and solutions that are used in the analysis of biological, food, and environmental samples. The Group now reports in three operating segments: Components and Consumables, Capital Equipment and Disruptive Technologies. Key revenue is generated from Components and consumables, which include parts, supplies, components, and consumable products worldwide. The Group operates in Asia (Malaysia, Japan and Australia and New Zealand (ANZ)), USA and Europe, Middle East, Africa, and India (EMEA).
38GF Score
Get the complete analysis for ASX:TRJ
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:TRJ has been successfully added to your 
